Aurobindo Pharma gets warning letter from USFDA for API facility

The action follows the recent inspection of the facility by the US Food and Drug Administration (USFDA) in August 2021, the drugmaker said in a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3qrxyL5
via IFTTT